SBFMW · Sunshine Biopharma, Inc.

On May 18, 2026, Sunshine Biopharma Inc. entered into a placement agent agreement with Aegis Capital Corp. for a best efforts public offering. The offering closed on May 19, 2026, raising approximately $6.0 million in gross proceeds before deducting placement agent fees and other expenses. The offering consisted of two types of units: Common Units, each comprising one share of common stock and two Series C Warrants, priced at $0.50 per unit, and Pre-Funded Units, each comprising one pre-funded warrant to purchase one share of common stock at $0.00001 and two Series C Warrants, priced at $0.49999 per unit. In total, 11,160,000 Common Units and 840,000 Pre-Funded Units were sold. The Series C Warrants are immediately exercisable at $0.50 per share and expire in five years. They include an anti-dilution feature: if the company undergoes a share combination event and the stock trades below the then‑effective exercise price for a specified period, the exercise price adjusts downward (but not below $0.25) with a corresponding increase in the number of warrant shares. This structure could yield up to $12.0 million in additional proceeds if all warrants are exercised. The company intends to use the net proceeds for general corporate purposes and working capital. Aegis Capital Corp. served as exclusive placement agent, receiving a 7% commission and a 2% non‑accountable expense allowance. Insiders agreed to 90‑day lock‑up restrictions. The offering provides Sunshine Biopharma with near‑term capital while potentially dilutive, and the warrant structure provides a path to additional funding if the stock performs.